Compare Ascendis Pharma A/S (ASND) vs Unilever plc (UL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Unilever plc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Unilever plc trades at $61.45 (market cap $130.72B). The key difference: Unilever plc is far larger — about 7.4× Ascendis Pharma A/S's market cap, and Unilever plc pays a 3.69% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | UL | |
|---|---|---|
Market Cap | $17.74B | $130.72B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $74.59 |
52-Week Low | $163.32 | $55.05 |
Enterprise Value | $18.11B | $156.17B |
Dividend Yield | — | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Unilever (UL) trades at $61.72, up 1.2% with a bullish technical signal despite recent earnings misses. The company maintains strong profitability with 18.75% net margins and 53.32% ROE, though revenue declined to $60.76B in 2024. Recent developments include a transformative food business deal with McCormick and a $270M innovation center investment, positioning for future growth amid current headwinds.
UL presents a mixed outlook with strong brand power and cash flow generation offset by recent earnings disappointments and competitive pressures. The stock appears fairly valued at 20.93 P/E, with analyst consensus divided between growth potential from strategic initiatives and concerns about execution risks in a challenging consumer environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
